Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

导出 LinkOut

翻译打印收藏纠错

作者： Stefano,Sacchi ^[1] ; Samantha,Pozzi ; Luigi,Marcheselli ; Alessia,Bari ; Stefano,Luminari ; Francesco,Angrilli ; Francesco,Merli ; Daniele,Vallisa ; Luca,Baldini ; Maura,Brugiatelli ; Italian Lymphoma Study Group

作者单位： Department of Oncology and Hematology, University of Modena, Modena, Italy. ssacchi@unimo.it ^[1]

主题词抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);无病生存(Disease-Free Survival);女(雌)性(Female);人类(Humans);淋巴瘤, 滤泡性(Lymphoma, Follicular);男(雄)性(Male);中年人(Middle Aged);复发(Recurrence);挽救疗法(Salvage Therapy);存活率(Survival Rate)

DOI 10.1002/cncr.22649

PMID 17394190

发布时间 2015-11-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览19

Cancer

2007年109卷10期

2077-82页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Cancer

相似文献

Cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Cancer

相似文献

Cancer

相关期刊

检索历史清除